Navigation Links
New High-Resolution Computer Tomography Data Demonstrates EVISTA(R)'s Effect on Bone Quality in Osteoporotic Patients
Date:6/28/2010

e-dimensional imaging technique called HRpQCT researchers were able to look inside the bone at the specific bone structure and quality. This provides a new approach to monitoring bone changes, especially while being treated medically for osteoporosis.

It was shown in clinical studies that raloxifene significantly increased BMD by 2% in both osteopenic and osteoporotic postmenopausal women compared to placebo(1). Compared with other osteoporotic drugs the numeric BMD increase with raloxifene is relatively low, although the vertebral fracture risk reduction is similar. The MORE (Multiple Outcome of Raloxifene Evaluation) study demonstrated that EVISTA(R) had a 55% relative risk reduction of vertebral fractures vs. placebo with a 2.4% absolute risk reduction in the risk of 1st vertebral fracture in patients with osteoporosis over 3 years(2). In addition, even the population of patients who lost BMD in the MORE study demonstrated a fracture risk reduction(3). Taking into account that bone strength is determined by both bone density and bone quality, it is assumed that less than 4% of fracture risk reduction is correlated to BMD after raloxifene treatment(3).

About Disease state for product information:

Osteoporosis, meaning 'porous bones' is a progressive disease which increases the risk of fracture, particularly in the spine, wrists and hips due to a reduction in bone strength. Osteoporosis can cause pain, loss of movement, inability to perform daily tasks, and in many cases, death. The declining level of oestrogen results in an increase in bone breakdown (resorption), which can lead to a loss of bone density and hence stability6.

About EVISTA(R):

EVISTA(R) (raloxifene 60mg) is a prescription medication called a Selective Estrogen Receptor Modulator (SERM). It is indicated for the treatm
'/>"/>

SOURCE Daiichi-Sankyo
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Virtual Microscope System from Hamamatsu Offers Faster Acquisition of High-Resolution Slide Scans
2. High-Resolution Breast PET Improves Breast Cancer Detection
3. New Computer-Based Tools Will Help Make Best Use of Genetic Breast Cancer Tests
4. GreenBytes Wards Off Germs and Costly Computer Repairs
5. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
6. Christiana Care Health System Rolls Out Electronic Computerized Provider Order Entry
7. Acuo Technologies Announces Patent for Asset Communication Format Within a Computer Network
8. Acuo Technologies Announces Patent Granted for Asset Communication Format Within a Computer Network
9. invendo medical Files 510(K) Notice With FDA for Clearance of the Computer-Assisted Colonoscopy System
10. National Patient Safety Foundation Awards Grant to Research Safety of Computerized Ordering of Medications
11. Eurotech Wins 1.5M USD Contract To Supply Embedded Computers For Medical Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015  Asterias Biotherapeutics, Inc. (NYSE ... emerging field of regenerative medicine, today announced that ... Chicago -based Rush University Medical Center ... of escalating doses of AST-OPC1 (oligodendrocyte progenitor cells) ... complete cervical spinal cord injury (SCI). This represents ...
(Date:8/31/2015)... WOODCLIFF LAKE, N.J. and STAMFORD, ... the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and ... into a worldwide collaboration agreement for the development and ... a dual orexin receptor antagonist entering Phase III clinical ... Under the terms of the agreement, Eisai and Purdue ...
(Date:8/31/2015)... Australia , Aug. 31, 2015 Bionomics ... discovery and development of innovative therapeutics for the treatment ... cancer, today announced that its BNC101 IND submission has ... (FDA). Bionomics plans to initiate a Phase 1 clinical ... patients with metastatic pancreatic cancer prior to 31 December ...
Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4
(Date:9/1/2015)... ... September 01, 2015 , ... ... borders seldom arise at the most convenient time for everyone involved. These occasions ... help. , Universal Translation Services has real people available to handle ...
(Date:9/1/2015)... ... 2015 , ... Dr. Trace Curry successfully placed one of the first ORBERA™ ... month the FDA has approved two intra-gastric balloons, the ORBERA ™ Managed Weight ... incisionless, reversible, weight loss procedures available to Americans. , Dr. Curry, medical ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... to send information about new patients directly from Practice Perfect to FOTO enabling ... data entry. , Steven Presement, President of Practice Perfect, stated ...
(Date:9/1/2015)... ... September 01, 2015 , ... Anthony J. Tantillo, Esq., Attorney from ... his third consecutive year in a row. Through nomination, research and strategic evaluation ... Born in Niagara Falls, New York, Tantillo is a Buffalo State College graduate of ...
(Date:9/1/2015)... ... September 01, 2015 , ... MediNatura™, the exclusive ... workshop for physician assistants (PAs) practicing in orthopedics. The workshop, titled “Treatment of ... by Dr. Erick Salado, an orthopedic surgeon at South Florida Bone and Joint ...
Breaking Medicine News(10 mins):Health News:Universal Translation Services Provides Quality Translations 24 Hours a Day Including Weekends 2Health News:Universal Translation Services Provides Quality Translations 24 Hours a Day Including Weekends 3Health News:Dr. Trace Curry Performs First ORBERA™ Intra-gastric Balloon in Ohio at JourneyLite, a New Incisionless Option For The Treatment of Obesity 2Health News:FOTO Announces New Integration Partnership with Practice Perfect 2Health News:New Hope for Patients Seeking Treatment of Osteoarthritis Knee Pain 2Health News:New Hope for Patients Seeking Treatment of Osteoarthritis Knee Pain 3
... May 19, 2009 (OAKLAND, Calif.) An e-mail intervention ... and physical activity by helping people move more, sit ... Kaiser Permanente Division of Research study in the ... was a randomized controlled trial of the ALIVE (A ...
... LIFE Event raises $500,000 for breast cancer bringing total ... Twenty-eight LPGA pros including World Golf Hall of ... players Angela Stanford, Morgan Pressel, Brittany Lincicome, Helen Alfredsson, ... for the 10th anniversary LIFE (LPGA Pros in the ...
... MEETING, Pa., May 18 /PRNewswire-Asia-FirstCall/ -- BMP Sunstone,Corporation (Nasdaq: ... the first quarter ended March 31, 2009. , , ... -- First quarter revenues increased to $39.3 million ... prior year period., -- Gross profit increased to ...
... 18 Gentiva Health Services, Inc. (Nasdaq: GTIV ), ... on May 14, 2009 it received official notification from Nasdaq that ... requirements as set forth in Listing Rule 5605. Under Nasdaq ... regain compliance as follows: , , ...
... Pharmaceuticals, Inc. (Nasdaq: TRBN ) announced today ... 2b study (15002) of TRU-015 for rheumatoid arthritis will ... League Against Rheumatism (EULAR) annual meeting in Copenhagen, Denmark. ... http://www.eular.org/ .(Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO ...
... The Quigley Corporation, (Nasdaq: QG L ... , today announced an update on the Company,s ... announcement regarding the unexpected positive finding for its QR-333 ... 11b clinical trial. While the complete statistical results of ...
Cached Medicine News:Health News:Workplace e-mail intervention program helps people sit less and eat better 2Health News:Workplace e-mail intervention program helps people sit less and eat better 3Health News:LIFE 10th Anniversary Event Delivers Big Names and Big Dollars for Breast Cancer Fight 2Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 2Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 3Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 4Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 5Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 6Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 7Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 8Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 9Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 10Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 11Health News:Gentiva(R) Health Services Receives Nasdaq Notification Regarding Independent Director Requirement 2Health News:Gentiva(R) Health Services Receives Nasdaq Notification Regarding Independent Director Requirement 3Health News:Trubion Pharmaceuticals, Inc. to Present Positive Data From a Phase 2b Re-treatment Study of TRU-015 at the 2009 EULAR Annual Meeting 2Health News:Trubion Pharmaceuticals, Inc. to Present Positive Data From a Phase 2b Re-treatment Study of TRU-015 at the 2009 EULAR Annual Meeting 3Health News:Trubion Pharmaceuticals, Inc. to Present Positive Data From a Phase 2b Re-treatment Study of TRU-015 at the 2009 EULAR Annual Meeting 4Health News:The Quigley Corporation Announces Update on Strategic Alternatives and Commitment to Additional Review of Current Cost Structure 2Health News:The Quigley Corporation Announces Update on Strategic Alternatives and Commitment to Additional Review of Current Cost Structure 3Health News:The Quigley Corporation Announces Update on Strategic Alternatives and Commitment to Additional Review of Current Cost Structure 4
... KeraCel Ophthalmic Products are ... formulation of lint-free MEROCEL polyvinyl ... configured to be beneficial to ... being absorbent, and yet firm ...
... Products provide the surgeon ... products for unparalleled fluid ... of fine microsurgical instruments. ... is highly absorbent, fast ...
... Merocel Ophthalmic Products provide ... fiber free products for ... safe cleaning of fine ... Merocel material is highly ...
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Medicine Products: